代谢性疾病和癌症期间的过氧化物酶体增殖物激活受体调节：主与仆。
Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.
作者信息
Vitale Salvatore Giovanni, Laganà Antonio Simone, Nigro Angela, La Rosa Valentina Lucia, Rossetti Paola, Rapisarda Agnese Maria Chiara, La Vignera Sandro, Condorelli Rosita Angela, Corrado Francesco, Buscema Massimo, D'Anna Rosario
机构信息
Unit of Gynecology and Obstetrics, Department of Human Pathology in Adulthood and Childhood ''G. Barresi", University of Messina, Messina, Italy.
Unit of Diabetology and Endocrino-Metabolic Diseases, Hospital for Emergency Cannizzaro, Catania, Italy.
出版信息
PPAR Res. 2016;2016:6517313. doi: 10.1155/2016/6517313. Epub 2016 Dec 28.
The prevalence of obesity and metabolic diseases (such as type 2 diabetes mellitus, dyslipidaemia, and cardiovascular diseases) has increased in the last decade, in both industrialized and developing countries. This also coincided with our observation of a similar increase in the prevalence of cancers. The aetiology of these diseases is very complex and involves genetic, nutritional, and environmental factors. Much evidence indicates the central role undertaken by peroxisome proliferator-activated receptors (PPARs) in the development of these disorders. Due to the fact that their ligands could become crucial in future target-therapies, PPARs have therefore become the focal point of much research. Based on this evidence, this narrative review was written with the purpose of outlining the effects of PPARs, their actions, and their prospective uses in metabolic diseases and cancers.
在过去十年中，肥胖症和代谢性疾病（如2型糖尿病、血脂异常和心血管疾病）在工业化国家和发展中国家的患病率均有所上升。这也与我们观察到的癌症患病率出现类似上升的情况相吻合。这些疾病的病因非常复杂，涉及遗传、营养和环境因素。大量证据表明，过氧化物酶体增殖物激活受体（PPARs）在这些疾病的发展过程中发挥着核心作用。由于其配体在未来的靶向治疗中可能至关重要，因此PPARs已成为众多研究的焦点。基于这一证据，撰写本叙述性综述的目的是概述PPARs的作用、它们的作用机制以及它们在代谢性疾病和癌症中的潜在用途。
Zotero 插件